- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04428983
The Effect of Hericium Erinaceus Mycelium in Non-motor Symptoms of Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Inclusion criteria:
- PD patients aged 50-79 years diagnosed by neurologist (should exclude vascular parkinsonism, secondary parkinsonism( including toxin, drug, heavy metal, CO intoxication), normal pressure hydrocephalus, multiple system atrophy, progressive supranuclear palsy, cortical basal degeneration, dementia with Lewy Body, hereditary parkinson's disease with genetic mutation, Huntington's disease, Wilson disease, spinal cerebellar ataxia with extrapyramidal syndrome, essential tremor, dystonia)
- PD at Hoehn and Yahr stage 2-2.5
- without cognitive decline
Exclusion criteria:
- with diabetes mellitus (DM)
- with nephropathy (GFR < 30ml/min)
- with significant neurological deficits caused by vascular insults
Measurement parameters:
- At recruitment: blood sugar, AST, ALT, BUN, Crea, Ca, Na, K and peripheral blood cell (for the expression levels of KATP)
- every 6 months: motor symptoms: UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS
- every 1 year: CASI, tilting table, AST, ALT, BUN, crea, Na, K, Ca
Protocol:
0 month (initial baseline):
- blood sugar, AST, ALT, BUN, Crea, Ca, Na, K and peripheral blood cell
- Tilting table test (autonomic function)
- CASI cognitive test
- UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS
- stool microbiota
6 months: UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS
12 months:
- UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS
- CASI cognitive test, tilting table, AST, ALT, BUN, crea, Na, K, Ca
18 months: UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS
24 months:
- UPDRS, evaluate with UDYSRS if presence with dyskinesia Non motor symptoms: self-report: PDQ39, QUIP, PDSS Rated by neurologist: NMSS, HAM-D, BPRS
- CASI cognitive test, tilting table, AST, ALT, BUN, crea, Na, K, Ca
- stool microbiota
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Li-Ya Lee
- Phone Number: 2995 +886-3-4572525
- Email: ly.lee@grapeking.com.tw
Study Locations
-
-
-
Tainan, Taiwan, 704
- Recruiting
- National Cheng Kung University Hospital
-
Contact:
- Yuan-Ting Sun, MD PhD
- Phone Number: +886-6-2353535
- Email: ytsun@mail.ncku.edu.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- idiopathic PD patients, aged 50-79 years
- modified Hoehn & Yahr stage 2-2.5
- Without subjective and objective cognitive decline (objective cognitive decline will be determined by CASI)
Exclusion Criteria:
- With diabetes
- With end stage renal disease under hemodialysis
- With significant vascular insults that resulted in significant neurological deficits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hericium erinaceus mycelium
Hericium erinaceus capsules 1 table tid orally per day for 24 months
|
Hericium erinaceus capsules 3 tables per day for 24 months
|
Placebo Comparator: placebo
placebo capsules 1 table tid orally per day for 24 months
|
Hericium erinaceus capsules 3 tables per day for 24 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
baseline
Time Frame: 0 month
|
Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
|
0 month
|
1st
Time Frame: 6 momths
|
Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
|
6 momths
|
2nd
Time Frame: 12 months
|
Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
|
12 months
|
3rd
Time Frame: 18 months
|
UPDRS
|
18 months
|
final
Time Frame: 24 months
|
Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
|
24 months
|
Collaborators and Investigators
Investigators
- Study Director: Li-Ya Lee, Bioengineering Center, Grape King Bio
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HELPD V4 20191120
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Hericium erinaceus mycelium
-
Chung Shan Medical UniversityActive, not recruitingHericium Erinaceus Mycelium and Probiotic of the Grape King Bio on Symptoms of Premenstrual SyndromePremenstrual SyndromeTaiwan
-
University of PrimorskaCompleted
-
Chung Shan Medical UniversityGrape King Bio Ltd.CompletedCognition Disorders in Old Age | fMRI | Vision | SupplementTaiwan
-
Chonbuk National University HospitalCompleted
-
Providence University, TaiwanUnknown
-
Chonbuk National University HospitalCompleted
-
National Cheng-Kung University HospitalGrape King Bio Ltd.RecruitingDepressive Disorder, MajorTaiwan